Bio-Pharm Archives - 17 중 3 번째 페이지

AbClon’s Nespe-cel CAR-T Therapy Gains Orphan Drug Status in Korea

AbClon, a Korean antibody drug developer, announced on September 18 that its next-generation CAR-T (chimeric antigen receptor T-cell) therapy Nespe-cel (AT101) has been designated as a developmental-stage orphan drug by…

Cheon Okhyeon

2025-09-18

SK Biopharm’s Cenobamate Shows Efficacy in Global Phase 3 Generalized Seizure Trial

Xcopri [Photo=SK Biopharm] SK Biopharm announced that its innovative epilepsy drug cenobamate has shown efficacy in patients with generalized seizures in a Phase 3 clinical trial, marking a key step…

Cheon Okhyeon

2025-09-16

HK inno.N “K-CAB Reduces Risk of Gastrointestinal Bleeding in Heart Attack Patients”

HK inno.N announced on the 10th that a recent comparative analysis has confirmed the safety and efficacy of its gastroesophageal reflux disease (GERD) drug 'K-CAB (tegoprazan)' against conventional proton pump…

Cheon Okhyeon

2025-09-10

KOREA UNITED PHARM Set to Surpass KRW 300 Billion in Sales This Year

KOREA UNITED PHARM, INC. is on track to exceed KRW 300 billion (USD 217 million) in annual sales for the first time in its history, backed by a steady stream…

Cheon Okhyeon

2025-09-01

GC Biopharma Files Phase 3 Trial for Two-Dose Chickenpox Vaccine in Thailand

GC Biopharma announced on the 27th that it has submitted an Investigational New Drug (IND) application to Thailand’s Food and Drug Administration for a Phase 3 clinical trial of its…

Cheon Okhyeon

2025-08-27

Fierce ADC Battlefield… Celltrion’s Bet Is on ‘biobetter’

Celltrion, which has entered the rapidly emerging field of antibody–drug conjugates (ADCs), is seeking to differentiate itself with a “biobetter ADC” that improves or overcomes the shortcomings of existing antibody…

Cheon Okhyeon

2025-08-25

Onconic Therapeutics Bets Its Future on Homegrown Drugs…from GERD to Pancreatic Cancer

Onconic Therapeutics’ first domestically developed drug, Zacubo, is rapidly growing in Korea and has now entered the regulatory process in China, the world’s largest gastroesophageal reflux disease (GERD) market. Adding…

Cheon Okhyeon

2025-08-19

Daewoong’s Microneedle Patch Hits 80% of Injection Efficiency

A microneedle patch for obesity treatment, delivering drug absorption rates close to those of injections, has moved a step closer to commercialization. Daewoong Pharmaceutical (Co-CEOs Park Seong-su and Lee Chang-jae)…

Cheon Okhyeon

2025-08-13

Celltrion Wins Successive Bids in Italian Regional Drug Tenders

Celltrion is expanding its presence in Italy as its autoimmune disease treatments and cancer therapies continue to secure wins in regional government tenders. Celltrion’s Italian subsidiary announced on August 12…

Cheon Okhyeon

2025-08-12

K-CAB Surge and Vaccine Distribution Put HK inno.N on the Verge of ₩1 Trillion in Annual Sales

HK inno.N is closing in on its first-ever annual sales of ₩1 trillion. According to financial data provider FnGuide on August 11, the company’s 2025 revenue is projected at ₩1.0969…

Cheon Okhyeon

2025-08-11